Expression and clinical relevance of cell division cycle associated 8 (CDCA8) gene in endometrial cancer patients

Objective: The cell division cycle associated 8 (CDCA8) gene is over- expressed in several cancers and has been associated with tumor progression. However, its expression and association with clinicopathological parameters and survival outcomes in patients with endometrial carcinoma (EC) remain obscure. Methods: We studied CDCA8 expression in EC patients utilizing data compiled by The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. We examined CDCA8 expression concerning clinicopathological features and patient overall survival. Gene set enrichment analysis (GSEA) was performed to identify potential biological processes and signaling pathways involved. Results: CDCA8 was over-expressed in EC tumors compared to control tissues and was positively associated with worse tumor grade, FIGO stage, tumor (T) stage, nodal spread (N), and metastasis (M). High CDCA8 was asso- ciated with shorter overall survival but did not remain a significant independent predictor in multivariate analysis. Gene set enrichment analysis revealed important signaling pathways that may contribute to EC pathogenesis. Conclusion: CDCA8 was overexpressed in EC and positively correlated with poor clinicopathological features. CDCA8 warrants further investigation as a prognostic biomarker and therapeutic target in patients with EC.

Endometrial cancer; Cell division cycle associated 8; Clinicopathological factors; Prognosis; Cancer biomarker

[1] Falconer H, Yin L, Altman D. Association between tubal ligation and endometrial cancer risk: a Swedish population-based cohort study. International Journal of Cancer. 2018; 143: 16–21.

[2] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016; 387: 1094–1108.

[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69: 7–34.

[4] Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research. 2014; 74: 2913–2921.

[5] Cancer Research UK. Uterine Cancer Statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer (Accessed: 17 March 2020).

[6] National Cancer Institute. Cancer stat facts: uterine cancer. Avail- able at: https://seer.cancer.gov/statfacts/html/corp.html (Accessed: 17 March 2020).

[7] Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecologic Oncology Research and Practice. 2017; 4: 19.

[8] McMeekin S, Dizon D, Barter J, Scambia G, Manzyuk L, Lisyanskaya A, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecologic Oncology. 2015; 138: 18–23.

[9] Howlader N, Noone AM, Krapcho M. SEER cancer statistics review (CSR) 1975–2016. National Cancer Institute. 2020.

[10] Aristizabal P, Graesslin O, Barranger E, Clavel-Chapelon F, Haddad B, Luton D, et al. A suggested modification to FIGO stage I endometrial cancer. Gynecologic Oncology. 2014; 133: 192–196.

[11] Wenzel ES, Singh ATK. Cell-cycle checkpoints and aneuploidy on the path to cancer. In Vivo. 2018; 32: 1–5.

[12] Hindriksen S, Meppelink A, Lens SMA. Functionality of the chromosomal passenger complex in cancer. Biochemical Society Transactions. 2015; 43: 23–32.

[13] Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nature Reviews Molecular Cell Biology. 2013; 13: 789–803.

[14] Haase J, Bonner MK, Halas H, Kelly AE. Distinct roles of the chromosomal passenger complex in the detection of and response to errors in kinetochore-microtubule attachment. Developmental Cell. 2017; 42: 640–654.e5.

[15] Bu Y, Shi L, Yu D, Liang Z, Li W. CDCA8 is a key mediator of estrogen-stimulated cell proliferation in breast cancer cells. Gene. 2019; 703: 1–6.

[16] Bi Y, Chen S, Jiang J, Yao J, Wang G, Zhou Q, et al. CDCA8 expression and its clinical relevance in patients with bladder cancer. Medicine. 2018; 97: e11899.

[17] Phan NN, Wang C, Li K, Chen C, Chiao C, Yu H, et al. Distinct expression of CDCA3, CDCA5, and CDCA8 leads to shorter relapse free survival in breast cancer patient. Oncotarget. 2019; 9: 6977–6992.

[18] Chang J, Chen T, Wang C, Chiang Y, Huang Y, Wong F, et al. Borealin/Dasra B is a cell cycle-regulated chromosomal passenger protein and its nuclear accumulation is linked to poor prognosis for human gastric cancer. Experimental Cell Research. 2006; 312: 962–973.

[19] Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV, Rao PH, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes, Chromosomes & Cancer. 2007; 46: 373–384.

[20] Ju W, Yoo BC, Kim I, Kim JW, Kim SC, Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2009; 18: 47–56.

[21] Hayama S, Daigo Y, Yamabuki T, Hirata D, Kato T, Miyamoto M, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Research. 2007; 67: 4113–4122.

[22] Wang Y, Zhao Z, Bao X, Fang Y, Ni P, Chen Q, et al. Borealin/Dasra B is overexpressed in colorectal cancers and contributes to proliferation of cancer cells. Medical Oncology. 2015; 31: 248.

[23] Ci C, Tang B, Lyu D, Liu W, Qiang D, Ji X, et al. Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis. International Journal of Molecular Medicine. 2019; 43: 404–412.

[24] Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2018; 19: 649–658.

[25] Urrego D, Tomczak AP, Zahed F, Stühmer W, Pardo LA. Potassium channels in cell cycle and cell proliferation. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences. 2014; 369: 20130094.

[26] Papini D, Langemeyer L, Abad MA, Kerr A, Samejima I, Eyers PA, et al. TD-60 links RalA GTPase function to the CPC in mitosis. Nature Communications. 2016; 6: 7678.

[27] Dai C, Miao C, Xu X, Liu L, Gu Y, Zhou D, et al. Transcriptional activation of human CDCA8 gene regulated by transcription factor NF-Y in embryonic stem cells and cancer cells. The Journal of Biological Chemistry. 2015; 290: 22423–22434.

[28] Jiao DC, Lu ZD, Qiao JH, Yan M, Cui SD, Liu ZZ. Expression of CDCA8 correlates closely with FOXM1 in breast cancer: public microarray data analysis and immunohistochemical study. Neoplasma. 2019; 62: 464–469.

[29] Chen C, Chen S, Luo M, Yan H, Pang L, Zhu C, et al. The role of the CDCA gene family in ovarian cancer. Annals of Translational Medicine. 2020; 8: 190.

[30] Liu J, Zhou S, Li S, Jiang Y, Wan Y, Ma X, et al. Eleven genes associated with progression and prognosis of endometrial cancer (EC) identified by comprehensive bioinformatics analysis. Cancer Cell International. 2020; 19: 136.

[31] Yu D, Shi L, Bu Y, Li W. Cell division cycle associated 8 is a key regulator of tamoxifen resistance in breast cancer. Journal of Breast Cancer. 2020; 22: 237–247.

[32] Date DA, Jacob CJ, Bekier ME, Stiff AC, Jackson MW, Taylor WR. Borealin is repressed in response to p53/Rb signaling. Cell Biology International. 2008; 31: 1470–1481.

Gao X, Wen XH, He HW, Zheng LL, Yang YB, Yang JL, et al. Knockdown of CDCA8 inhibits the proliferation and enhances the apoptosis of bladder cancer cells. PeerJ. 2020; 8: e9078.